Entrada Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Entrada Therapeutics R&D Spending Growth & History (TRDA)
Entrada Therapeutics's r&d spending was $142.3M for fiscal 2025.
View full Entrada Therapeutics company overviewEntrada Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $142.3M | $17.0M | +13.54% |
| 2024 | 2024-12-31 | $125.3M | $25.4M | +25.45% |
| 2023 | 2023-12-31 | $99.9M | $33.3M | +49.96% |
| 2022 | 2022-12-31 | $66.6M | $30.7M | +85.41% |
| 2021 | 2021-12-31 | $35.9M | $14.8M | +70.25% |
| 2020 | 2020-12-31 | $21.1M | — | — |
Entrada Therapeutics quarterly r&d spending
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $35.4M | −$2.5M | −6.62% |
| Q1 2026 | 2026-03-31 | $33.1M | $980,000 | +3.06% |
| Q4 2025 | 2025-12-31 | $34.0M | $551,000 | +1.65% |
| Q3 2025 | 2025-09-30 | $38.4M | $7.1M | +22.73% |
| Q2 2025 | 2025-06-30 | $37.9M | $5.8M | +18.24% |
| Q1 2025 | 2025-03-31 | $32.1M | $3.5M | +12.12% |
| Q4 2024 | 2024-12-31 | $33.4M | $5.1M | +18.08% |
| Q3 2024 | 2024-09-30 | $31.3M | $9.1M | +40.85% |
| Q2 2024 | 2024-06-30 | $32.0M | $5.7M | +21.81% |
| Q1 2024 | 2024-03-31 | $28.6M | $5.5M | +23.83% |
| Q4 2023 | 2023-12-31 | $28.3M | $12.6M | +80.37% |
| Q3 2023 | 2023-09-30 | $22.2M | $3.2M | +17.05% |
| Q2 2023 | 2023-06-30 | $26.3M | $10.1M | +61.87% |
| Q1 2023 | 2023-03-31 | $23.1M | $7.4M | +46.98% |
| Q4 2022 | 2022-12-31 | $15.7M | $3.3M | +26.89% |
| Q3 2022 | 2022-09-30 | $19.0M | $8.4M | +80.33% |
| Q2 2022 | 2022-06-30 | $16.2M | $9.4M | +137.93% |
| Q1 2022 | 2022-03-31 | $15.7M | $9.5M | +152.58% |
| Q4 2021 | 2021-12-31 | $12.4M | — | — |
| Q3 2021 | 2021-09-30 | $10.5M | $4.8M | +84.44% |
| Q2 2021 | 2021-06-30 | $6.8M | — | — |
| Q1 2021 | 2021-03-31 | $6.2M | — | — |
| Q3 2020 | 2020-09-30 | $5.7M | — | — |
Entrada Therapeutics r&d spending trends
Over the last five fiscal years, Entrada Therapeutics's r&d spending increased from $21.1M to $142.3M, a change of $121.2M. The latest reported quarter, Q2 2026, shows $35.4M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Entrada Therapeutics source filings ↗